Clinical Trials Logo

Filter by:
NCT ID: NCT06211140 Recruiting - Clinical trials for Major Depressive Disorder

Transcranial Alternating Current Stimulation (tACS) on Serotonin-1A Receptor in Depression

Start date: January 31, 2024
Phase: N/A
Study type: Interventional

This study will apply a comprehensive tools that integrates neuroimaging, psychological evaluation, and sleep monitoring through 18F-MPPF PET/MR, neuropsychological tests, and polysomnography (PSG) to explore the neurobiological mechanisms underlying transcranial alternating current stimulation (tACS) for depressive disorders, mainly focusing on the serotonergic system revealed by Serotonin-1A (5-HT1A) receptor.

NCT ID: NCT06211127 Recruiting - Clinical trials for Atherosclerosis of Artery

Safety and Efficacy of Cold Laser Plaque Ablation for Lower Limb Arterial Stenosis and Occlusive Lesions

Start date: October 16, 2023
Phase: N/A
Study type: Interventional

This study is a prospective, multi-center, randomized controlled study, which evaluates the effectiveness and safety of cold laser plaque ablation for lower limb arterial stenosis and occlusive lesions from intermittent claudication to chronic threatening limb ischemia.

NCT ID: NCT06211036 Recruiting - Clinical trials for Small-Cell Lung Cancer

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

DeLLphi-305
Start date: June 5, 2024
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

NCT ID: NCT06210815 Recruiting - Solid Tumor Clinical Trials

A Study of HLX42 in Advanced/Metastatic Solid Tumors

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.

NCT ID: NCT06210776 Recruiting - Breast Cancer Clinical Trials

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Start date: January 15, 2024
Phase:
Study type: Observational

This multi-center observational prospective study will collect real-world clinical and patient-reported outcome data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more prior anti-HER2-based regimens or patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+, ISH-) breast cancer who have received at least a prior systemic therapy in the metastatic setting, or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

NCT ID: NCT06210633 Recruiting - Stroke, Acute Clinical Trials

Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke

XL-STROKE
Start date: January 20, 2024
Phase:
Study type: Observational [Patient Registry]

Since 2015, many randomized trials have shown that endovascular thrombectomy improve functional outcomes in acute ischemic stroke patients with large vessel occlusion. Recently, five randomized controlled trials (ANGEL-ASPECT [Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core], LASTE [LArge Stroke Therapy Evaluation], RESCUE-Japan LIMIT [The Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism-Japan Large Ischemic Core Trial], SELECT 2 [Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke], and TENSION [The Efficacy and Safety of Thrombectomy in Stroke with extended lesion and extended time window]) demonstrated the efficacy and safety of thrombectomy for large infarct patients (defined as Alberta Stroke Program Early Computed Tomography Score [ASPECTS] ≥3 or infarct core <100ml). Patients with extra-large infarct core (volume greater than 100 mL, ASPECTS score of 2 or less) were excluded from these trials. Therefore, the efficacy of endovascular thrombectomy in patients with extra-large ischemic burden has not been well studied. The XL STROKE registry is aiming to investigate the clinical outcomes and safety of mechanical thrombectomy in acute extra-large ischemic stroke.

NCT ID: NCT06210529 Recruiting - Breast Cancer Clinical Trials

Clinical Study of High-intensity Focused Ultrasound Tumor Treatment System(Super Knife) in the Treatment of Breast Cancer

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Breast cancer is the most common cancer diagnosed among women and is the second leading cause of cancer death among women after lung cancer. The treatment methods of breast cancer include surgery, chemotherapy, radiotherapy and so on. The investigators discover a High-intensity focused ultrasound therapy to treat breast tumor, which is a non-invasive method.

NCT ID: NCT06210425 Recruiting - Sepsis Clinical Trials

Is Re-examination of Urine Culture Necessary for Patients With Preoperative Positive Results in Predicting Infectious Complications Related to Mini-Percutaneous Nephrolithotomy?

Start date: March 1, 2021
Phase:
Study type: Observational

Objective To explore the predictive value of urine culture re-examination in identifying infectious complications associated with mini-PCNL in patients with preoperative positive urine culture who were treated with sensitive antibiotics. Methods Prospective and consecutive clinical data were collected from patients whose preoperative urine culture was positive and who underwent PCNL at the Department of Urology, the First Affiliated Hospital of Guangzhou Medical University. If patients'preoperative urine cultures were positive, they would be treated with appropriate antibiotics in accordance with the culture-antibiogram test results, and urine cultures were repeated on day 3 and day 7. Patients would undergo mini-PCNL after the treatment of sensitive antibiotics for 7 days, and the correlation between the results of urine culture on day 3 and day 7 and infectious complications related to mini-PCNL after surgery was analyzed.

NCT ID: NCT06210243 Recruiting - Lymphoma, B-Cell Clinical Trials

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Start date: December 24, 2023
Phase: Phase 1
Study type: Interventional

It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.

NCT ID: NCT06210100 Recruiting - Suicidal Ideation Clinical Trials

aiTBS for NSSI and Suicide in Adolescent Depression

Start date: January 18, 2024
Phase: N/A
Study type: Interventional

Repetitive transcranial magnetic stimulation (rTMS) has been successfully used to help patients with treatment resistant depression. However, its role in alleviating self injuries with and without suicidal ideation remained uncertain. This trial will compare the effectiveness of active accelerated intermittent theta burst stimulation (aiTBS) rTMS to a placebo control on non-suicidal self injury (NSSI) and suicidal attempts in patients with major depressive disorder.